+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years - 75Years
All Genders
ID07631637

Evaluation of ALN-CIDEB Versus Placebo for Liver Fat Reduction in Adults With Fibrotic Metabolic Dysfunction-Associated Steatohepatitis

Led by Regeneron Pharmaceuticals · Updated on 2026-10-26

150

Participants Needed

16

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating a drug called ALN-CIDEB to explore its potential in treating metabolic dysfunction-associated steatohepatitis MASH, a type of liver disease marked by liver fat, injury, and scarring. This Phase 2b randomized, double-blind, placebo-controlled study aims to compare ALN-CIDEB against placebo to understand its impact on reducing liver fat and improving liver health. Participants in this study will receive either one of two doses of ALN-CIDEB or a placebo, administered according to the study protocol. The study will monitor participants over a treatment period that includes assessments at 26 weeks and 52 weeks, evaluating changes in liver fat through MRI scans and liver biopsies, as well as safety and side effects. The study also includes follow-up to assess treatment-emergent adverse events up to 64 weeks. During the study, participants will undergo multiple evaluations including MRI-derived liver fat measurements, liver biopsies, FibroScan tests, blood tests for liver enzymes, and fibrosis markers. Researchers will track how liver fat, injury, and scarring change over time, as well as any side effects experienced. The study is sponsored by Regeneron Pharmaceuticals and is designed to collect detailed information over a period extending up to 64 weeks to better understand how ALN-CIDEB affects liver disease in adults aged 18 to 75 years.

CONDITIONS

Brief Title

Study to Evaluate ALN-CIDEB in Adults With Fibrotic Metabolic Dysfunction-Associated Steatohepatitis (MASH)

Research Team

C

Clinical Trials Administrator

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here